6/28/23, 11:01 PM LPV/r for COVID-19 Pathway Feedback Search Clinical Topics Home Studies LPV/r for COVID 19 LPV/r for COVID 19 Disease COVID 19 infection Trial question What is the role of lopinavir-ritonavir in patients with severe COVID-19? Study design Single center Open label RCT Population Characteristics of study participants 33.3% female N = 199 66.7% male 199 patients (59 female, 120 male) Inclusion criteria: hospitalized adult patients with severe COVID-19 Key exclusion criteria: pregnancy or breast-feeding, known severe liver disease, known HIV infection Interventions N=99 lopinavir-ritonavir (for 14 days) N=100 no antiviral therapy (standard of care) Primary outcome Time to clinical improvement 16.0 days 16 16 https://web.pathway.md/studies/recCxgJ6Na5PI7p9x 1/2 6/28/23, 11:01 PM LPV/r for COVID-19 Pathway y 6 6 12.0 days 8.0 days 4.0 days No significant difference 0.0 days Lopinavir-ritonavir No antiviral therapy No significant difference in time to clinical improvement (16 days vs. 16 days; HR 1.31, 95% CI 0.95 to 1.85) Safety outcomes No significant difference in adverse events (48.4% vs. 49.5%). Conclusion In hospitalized adult patients with severe COVID-19, lopinavir-ritonavir was not superior to no antiviral therapy with respect to time to clinical improvement. Reference Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid- 19. N Engl J Med. 2020 May 7;382(19):1787-1799. Open reference URL https://web.pathway.md/studies/recCxgJ6Na5PI7p9x 2/2